Must reads

• A September 30, 2013 Boston Globe article profiled Harvard development professional Charlie Collier's efforts to raise Alzheimer's awareness through patient advocacy. According to the article, "For 25 years, Charlie Collier traveled the country, seeking donations for Harvard University, where he gained a national reputation in the field of family philanthropy. Now, he is speaking out, as much as he is able, on a topic even closer to his heart: Alzheimer’s disease.Five years ago, at age 60, Collier was diagnosed with early onset Alzheimer’s."
• A September 29, 2013 BBC News article explored the impact of early on-set Alzheimer's. According to the article, "When Louise was three, her mother Zoe, who was then 29, was diagnosed with dementia. She is now 42, and living in a care home unable to walk or talk. Zoe is one of the 17,000 people in the UK living with "early-onset dementia", which is defined as cases diagnosed before the age of 65.
• A September 29, 2013 IndyStar.com article reported on Lilly's efforts to develop an effective Alzheimer's drug including renewed interest in solanezumab. According to the article, "The Indianapolis drug ­maker’s progress has been halting: Two of the drugs stumbled over safety or efficacy issues during tests, and the third is in the earliest stage of human testing, still years away from getting onto the market. The candidate that excites Wall Street the most for its sales potential is solanezumab, an intravenous treatment that targets the buildup of brain plaque known as beta amyloid, thought to be a basis of Alzheimer’s."